Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date

Anthracyclines, and doxorubicin in particular, remain a mainstay of sarcoma therapy. Despite modest activity and significant toxicities, no cytotoxic monotherapy has yet yielded superior overall survival over doxorubicin for therapy of advanced soft tissue sarcomas in a randomized trial. Similarly,...

Descripción completa

Detalles Bibliográficos
Autor principal: Cranmer, Lee D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430065/
https://www.ncbi.nlm.nih.gov/pubmed/30936721
http://dx.doi.org/10.2147/OTT.S145539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430065/
https://www.ncbi.nlm.nih.gov/pubmed/30936721
http://dx.doi.org/10.2147/OTT.S145539

Ejemplares similares